Open AccessIS ALLOGENEIC TRANPLANTATION AN OPTION IN PATIENTS AFFECTED BY CONCURRENT MYELOFIBROSIS AND CHRONIC MYELOID LEUKEMIA (CML)?
Author(s) -
Federica Sorà,
Patrizia Chiusolo,
Francesco Autore,
Sabrina Giammarco,
Luca Laurenti,
Idanna Innocenti,
Elisabetta Metafuni,
Eugenio Galli,
Andrea Bacigalupo,
Simona Sica
Publication year - 2021
Publication title -
mediterranean journal of hematology and infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 31
ISSN - 2035-3006
DOI - 10.4084/mjhid.2021.062
Subject(s) - medicine , ruxolitinib , myelofibrosis , myeloid leukemia , nilotinib , imatinib mesylate , myeloproliferative neoplasm , imatinib , polycythemia vera , philadelphia chromosome , tyrosine kinase inhibitor , transplantation , clone (java method) , population , oncology , tyrosine kinase , myeloid , dasatinib , bone marrow , gene , cancer , chromosomal translocation , genetics , biology , receptor , environmental health
Classification of myeloproliferative neoplasms is based on hematologic, histopathologic and molecular characteristics including the presence of the BCR-ABL1 and JAK2 V617F or MPL and CALR. Although the different gene mutations ought to be mutually exclusive, a number of cases with co-occurring BCR-ABL1 and JAK2 V617F or CALR, have been identified with a frequence of 0.2-2.5%in European population .The tyrosine kinase abnormalities appeared to affect independent subclones because imatinib mesylate (IM) treatment induced Ph+-CML remission whereas the JAK2V617F clone either persisted or clinically expanded after major response of Ph+-clone.
Allogeneic stem cell transplantation is at the present the only potentially curative therapy for these patients after therapy with ruxolitinib and TKI inhibitor. We describe the case of 3 young people treated in our institution for coexistence of BCR/ABL chronic myeloid leukemia and another Philadelphia chromosome negative (Ph−) CMPD. They received ruxolitinib, imatinib/nilotinib and allogeneic transplantation with a safe and efficient results.